SHERIDAN, WYOMING – May 9, 2025 – Galderma, a global leader in dermatology, has launched its highly anticipated "Scratch Resistance" campaign to help those living with atopic dermatitis (eczema). This new initiative highlights not only the physical burden of relentless itching but also the emotional toll it takes on individuals. The campaign focuses on encouraging patients to seek treatment with NEMLUVIO® (nemolizumab-ilto), a breakthrough treatment for atopic dermatitis that targets the root causes of itching and inflammation.
A Comprehensive Approach to Atopic Dermatitis
Atopic dermatitis, affecting millions of people in the U.S., is often seen as a condition marked by persistent itching. However, the impact goes far beyond the physical discomfort. Uncontrollable scratching can lead to sleep disturbances, anxiety, frustration, and even depression. In response to this, Galderma’s campaign is designed to validate these emotional and physical challenges, with a clear message: relief is possible.
As Debra Hagan, Vice President, General Manager, and Head of U.S. Therapeutic Dermatology at Galderma, explains, "Itch is the most common symptom of atopic dermatitis, but the impact of itch is often more than skin deep. Unrelenting itch can have a significant emotional burden." The "Scratch Resistance" campaign underscores Galderma's commitment to helping patients regain control of their lives by offering them a chance to overcome both the physical and emotional struggles associated with the disease.
Empowering Patients with NEMLUVIO®
NEMLUVIO® (nemolizumab-ilto) is the first and only approved neuroimmune-targeted treatment for atopic dermatitis. It works by directly targeting IL-31, a protein that is a key driver of itching, inflammation, and skin barrier dysfunction in people with eczema. By addressing the root cause of the symptoms, NEMLUVIO offers rapid relief from itching, often starting within 48 hours of treatment. This innovative treatment not only alleviates the need to scratch but also allows the skin to heal, bringing long-awaited relief to sufferers.
With FDA approval for patients aged 12 and older, NEMLUVIO is available in combination with topical therapies for those whose condition is not adequately controlled with traditional treatments. As of December 2024, it is approved for treating moderate-to-severe atopic dermatitis and is rapidly gaining attention for its ability to provide quick and effective relief.
A Multichannel Campaign to Reach More People
The "Scratch Resistance" campaign will air across multiple platforms, including national TV channels and social media platforms like Facebook and Instagram. The campaign creatively showcases the lengths to which individuals with atopic dermatitis often go to relieve their itching—whether using unusual objects or methods to scratch—and emphasizes that with NEMLUVIO, they can finally break free from this cycle of discomfort.
The campaign is designed to resonate with those who are frustrated with their current treatments and to show them that relief is just a step away. As the campaign rolls out, it aims to engage more patients in taking control of their condition and seeking the right treatment.
Why NEMLUVIO® Could Be the Solution You’ve Been Searching For
For many patients, atopic dermatitis is more than just an itchy skin condition—it affects their ability to live a full, happy life. NEMLUVIO® offers a solution that targets the disease at its core, providing rapid relief and improved quality of life for those suffering. With its proven track record and a growing number of patients experiencing significant improvement, NEMLUVIO is quickly becoming a trusted option for those with moderate-to-severe eczema.
If you're tired of the constant itch and want to regain control over your life, NEMLUVIO® may be the treatment you've been looking for. To learn more about how NEMLUVIO can help you, visit www.NEMLUVIO.com.
Conclusion: A New Hope for Eczema Sufferers
The "Scratch Resistance" campaign by Galderma brings a new hope for those suffering from atopic dermatitis. By addressing both the physical and emotional impacts of the condition, the campaign encourages patients to take action and explore effective treatment options like NEMLUVIO®. With rapid relief and the potential to restore skin health, NEMLUVIO offers a chance for sufferers to feel like themselves again. Don't let eczema control your life—find out more about this innovative treatment today!